| Literature DB >> 35455273 |
Juan Yang1, Yuting Liao1, Qianhui Hua2, Huakun Lv3.
Abstract
New vaccines are being developed in response to the coronavirus disease 2019 (COVID-19) pandemic. Vaccination provides a crucial preventive approach for managing COVID-19. We investigated adults' willingness to take COVID-19 vaccines in the Zhejiang province, and their cognitions regarding COVID-19, when the COVID-19 vaccine is authorized under Emergency Use Administration. An online survey was conducted from September to October 2020, which included social-demographic characteristics, risk perception, acceptance and influencing factors in relation to COVID-19 vaccines. Multivariate logistic regression was performed to identify the influencing factors of vaccination acceptance. Of the participants, 70% intended to be vaccinated when the COVID-19 vaccine was approved under Emergency Use Administration, among 2171 valid questionnaires. Logistic regression revealed that being male, having a high cognitive score regarding COVID-19, the belief that the COVID-19 vaccine is safe and effective, and the belief that one will be infected with SARS-CoV-2 this fall and winter, were associated with a greater probability of accepting vaccination. Respondents with junior college/university education or above were less likely to accept vaccination. Concerns about the safety and effectiveness of the vaccine were the main factors hindering vaccination acceptance. Health education is important for promoting accurate public knowledge regarding COVID-19 vaccination.Entities:
Keywords: COVID-19; SARS-CoV-2; emergence use administration; influencing factors; knowledge; vaccine acceptance
Year: 2022 PMID: 35455273 PMCID: PMC9027136 DOI: 10.3390/vaccines10040524
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Demographic characteristics of participants.
| Items | Respondents ( |
|---|---|
| Gender | |
| Male | 857 (39.5) |
| Female | 1314 (60.5) |
| Age group | |
| 18–30 | 639(29.4) |
| 31–40 | 698(32.2) |
| 41–50 | 528 (24.3) |
| ≥51 | 306 (14.1) |
| Region | |
| Urban | 1632 (75.2) |
| Rural | 539 (24.8) |
| Highest level of education | |
| Technical secondary school and below | 253 (11.7) |
| Junior College/University | 1559 (71.8) |
| Master’s degree or above | 359 (16.5) |
| Monthly income/CNY | |
| ≤3000 | 290 (13.4) |
| 3001–5000 | 524 (24.1) |
| 5001–10,000 | 840 (38.7) |
| >10,000 | 517 (23.8) |
Participants’ responses to COVID-19 related knowledge.
| Items | Ture/% | False/% | Unclear/% |
|---|---|---|---|
| COVID-19 is an acute viral infection | 91.20 | 4.88 | 3.92 |
| COVID-19 is spreading worldwide and can infect anyone in any age | 99.12 | 0.23 | 0.64 |
| COVID-19 can not spread among people easily | 1.38 | 97.88 | 0.74 |
| COVID-19 is a serious disease that can cause death | 94.10 | 3.04 | 2.86 |
| COVID-19 is not a serious public health problem | 3.59 | 94.01 | 2.40 |
| COVID-19 affects the economy by reducing labor productivity and increasing the burden of healthcare costs | 81.85 | 11.42 | 6.73 |
| COVID-19 infection is more serious and has a higher mortality rate in older people | 92.95 | 2.99 | 4.05 |
| Contracting COVID-19 is more severe for people with chronic diseases, with higher mortality rates | 92.03 | 2.16 | 5.80 |
| There are specific drugs for the treatment of COVID-19 | 7.55 | 73.19 | 19.25 |
| Vaccination is the most effective way to prevent COVID-19 and its complications | 81.85 | 5.53 | 12.62 |
Participants’ responses to the mode of transmission of COVID-19.
| Propagation Mode of COVID-19 | True/% | False/% | Unclear/% |
|---|---|---|---|
| Transmission by droplets from an infected person (talking, coughing, sneezing) | 99.59 | 0.18 | 0.23 |
| Shaking hands with an infected person | 79.92 | 16.90 | 3.18 |
| Touch elevators, tables, door handles, handrails, coins or paper money | 88.95 | 7.88 | 3.18 |
| Contact pets | 51.08 | 33.44 | 15.48 |
| Exposure to faecal contaminants (public toilets) | 87.47 | 7.23 | 5.30 |
| Frozen food imported from abroad (seafood, meat) | 86.27 | 6.77 | 6.96 |
| Aerosols (aerosols formed when droplets are mixed in the air and can cause infection when inhaled) | 95.49 | 1.80 | 2.72 |
Participants’ responses to symptoms and manifestations of COVID-19 infection.
| COVID-19 Infection Symptoms or Manifestations | True/% | False/% | Unclear/% |
|---|---|---|---|
| Fever | 98.85 | 0.41 | 0.74 |
| Cough | 97.60 | 0.78 | 1.61 |
| Fatigue | 98.11 | 0.60 | 1.29 |
| Rhinobyon/running nose | 85.17 | 7.51 | 7.32 |
| Pharyngalgia | 92.49 | 2.90 | 4.61 |
| Myalgia | 92.40 | 3.27 | 4.33 |
| Vomiting/diarrhea | 87.98 | 5.11 | 6.91 |
| Dyspnea | 97.47 | 0.74 | 1.80 |
Participants’ responses to preventive measures for SARS-CoV-2 infection.
| Preventive Measures for SARS-CoV-2 Infection | True/% | False/% | Unclear/% |
|---|---|---|---|
| Frequent hand-washing | 99.77 | 0.14 | 0.09 |
| Keep a distance from people | 99.72 | 0.18 | 0.09 |
| Avoid rubbing eyes, mouth and nose | 98.89 | 0.60 | 0.51 |
| Wear a mask in public | 99.95 | 0.05 | 0.00 |
| Try not to touch elevator buttons, door handles and other public facilities directly | 99.12 | 0.37 | 0.51 |
| Ventilate the Room | 99.36 | 0.32 | 0.32 |
| Take antibiotics | 14.37 | 72.96 | 12.67 |
| Eat garlic | 17.55 | 65.27 | 17.18 |
| COVID-19 vaccination | 95.12 | 0.69 | 4.19 |
Frequency distribution and chi-squared analysis of intentions of COVID-19 vaccination under EUA.
| Items | Willing to Vaccinate (%) | Reluctance to Vaccinate (%) |
|
|
|---|---|---|---|---|
| Gender | 32.06 | <0.001 | ||
| Male | 76.8 | 23.2 | ||
| Female | 65.4 | 34.6 | ||
| Age | 26.76 | <0.001 | ||
| 18–30 | 63.5 | 36.5 | ||
| 31–40 | 70.6 | 29.4 | ||
| 41–50 | 70.8 | 29.2 | ||
| ≥51 | 79.7 | 20.3 | ||
| Region | 1.52 | 0.218 | ||
| Urban | 69.2 | 30.8 | ||
| Rural | 72.0 | 28.0 | ||
| Highest level of education | 40.454 | <0.001 | ||
| Technical secondary school and below | 85.8 | 14.2 | ||
| Junior College/University | 69.0 | 31.0 | ||
| Master degree or above | 62.4 | 37.6 | ||
| Monthly income/CNY | 10.876 | 0.012 | ||
| ≤3000 | 66.2 | 33.8 | ||
| 3001–5000 | 72.7 | 27.3 | ||
| 5001–10,000 | 72.1 | 27.9 | ||
| >10,000 | 65.4 | 34.6 | ||
| Scores of COVID-19 related knowledge | 15.47 | <0.001 | ||
| ≥9 | 72.3 | 27.7 | ||
| [8, 9) | 64.4 | 35.6 | ||
| <8 | 62.7 | 37.3 | ||
| Scores of COVID-19 transmission | 2.66 | 0.265 | ||
| ≥9 | 69.4 | 30.6 | ||
| [8, 9) | 71.1 | 28.9 | ||
| <8 | 67.4 | 32.6 | ||
| Scores of COVID-19 infection symptoms | 0.647 | 0.724 | ||
| ≥9 | 69.5 | 30.5 | ||
| [8, 9) | 70.2 | 29.8 | ||
| <8 | 71.9 | 28.1 | ||
| Scores of COVID-19 prevention measures | 3.75 | 0.153 | ||
| ≥9 | 71.1 | 28.9 | ||
| [8, 9) | 66.2 | 33.8 | ||
| <8 | 70.4 | 29.6 | ||
| You will be infected with SARS-CoV-2 this fall and winter | 25.38 | <0.001 | ||
| Yes | 87.3 | 12.7 | ||
| Uncertain | 80.9 | 19.1 | ||
| No | 68.4 | 31.6 | ||
| COVID-19 will break out again this year | 24.53 | <0.001 | ||
| Yes | 77.1 | 22.9 | ||
| uncertain | 72.3 | 27.7 | ||
| No | 66.1 | 33.9 | ||
| Views on the safety of COVID-19 vaccine | 291.82 | <0.001 | ||
| Safe | 88.7 | 11.3 | ||
| Uncertain | 85.7 | 14.3 | ||
| Insecurity | 53.7 | 46.3 | ||
| Views on the protective effect of COVID-19 vaccine | 276.41 | <0.001 | ||
| Effective | 89.6 | 10.4 | ||
| Uncertain | 83.5 | 16.5 | ||
| Ineffective | 54.2 | 45.8 |
Multivariate logistic regression analysis of influencing factors of the respondents’ willingness to vaccinate against COVID-19.
| Characteristics | OR | 95% CI | |
|---|---|---|---|
| Gender | |||
| Female | Ref | ||
| Male | 1.54 | 1.24–1.92 | <0.001 |
| Highest level of education | |||
| Technical secondary school and below | Ref | ||
| Junior College/University | 0.45 | 0.30–0.68 | <0.001 |
| Master degree or above | 0.35 | 0.22–0.56 | <0.001 |
| Scores of COVID-19 related knowledge | |||
| <8 | Ref | ||
| [8, 9) | 0.98 | 0.68–1.44 | 0.929 |
| ≥9 | 1.46 | 1.06–2.00 | 0.020 |
| Views on the safety of COVID-19 vaccine | |||
| Insecurity | Ref | ||
| Uncertain | 3.17 | 2.32–4.33 | <0.001 |
| Safe | 2.56 | 1.68–3.92 | <0.001 |
| Views on the protective effect of COVID-19 vaccine | |||
| Ineffective | Ref | ||
| Uncertain | 2.45 | 1.81–3.31 | <0.001 |
| Effective | 3.06 | 1.99–4.71 | <0.001 |
| I will be infected with SARS-CoV-2 this fall and winter | |||
| No | Ref | ||
| Uncertain | 2.38 | 1.09–5.20 | 0.030 |
| Yes | 2.18 | 1.27–3.77 | 0.005 |
Reasons for willingness or unwillingness to receive the COVID-19 vaccine once it is authorized under Emergency Use Administration (EUA) n (%).
| Reasons | Disagree Strongly | Disagree | Neutral or Unknown | Agree | Agree Strongly |
|---|---|---|---|---|---|
| Reasons for willingness to receive COVID-19 vaccine | |||||
| COVID-19 vaccination is safe | 19 (1.17) | 12 (0.74) | 238 (14.67) | 538 (33.17) | 815 (50.25) |
| Vaccination is very effective in preventing COVID-19 | 14 (0.86) | 9 (0.55) | 241 (14.86) | 554 (34.16) | 804 (49.57) |
| Can protect family/friends/colleagues from infection | 22 (3.54) | 22 (1.36) | 176 (10.85) | 471 (29.04) | 931 (57.40) |
| Vaccination is beneficial if recommended by the country | 18 (1.11) | 7 (0.43) | 120 (7.4) | 465 (28.67) | 1012 (62.39) |
| Reasons for reluctance to get the COVID-19 vaccine | |||||
| There are no COVID-19 cases in the region and no vaccinations are required | 155 (2.63) | 75 (13.66) | 146 (26.59) | 86 (15.66) | 87 (15.85) |
| Doubting about the effectiveness of the COVID-19 vaccine | 80 (14.58) | 69 (12.57) | 181 (32.97) | 123 (22.40) | 96 (17.49) |
| Worrying about the side effects of the COVID-19 vaccine | 40 (7.29) | 38 (6.92) | 138 (25.14) | 168 (30.60) | 165 (30.05) |
| Community health service centers are not convenient for vaccination | 263 (47.91) | 105 (19.13) | 111 (20.22) | 37 (6.74) | 33 (6.01) |